Skip to main content
Top
Published in: Journal of Clinical Immunology 3/2013

01-04-2013 | Original Research

Serum Adenosine Deaminase and Total Immunoglobulin G Correlate with Markers of Immune Activation and Inversely with CD4 Counts in Asymptomatic, Treatment-Naive HIV Infection

Authors: Hayley Ipp, Annalise E. Zemlin, Richard H. Glashoff, Johan van Wyk, Naadira Vanker, Tim Reid, Linda-Gail Bekker

Published in: Journal of Clinical Immunology | Issue 3/2013

Login to get access

Abstract

Purpose

HIV-infection is characterized by aberrant immune activation and ongoing inflammation. Markers of inflammation are now recognized to have prognostic value for adverse events, independent of viral loads and CD4 counts. This study aimed to delineate a panel of affordable markers of immune activation in untreated HIV-infection that may have an impact on the management of HIV in resource-limited settings.

Methods

This was a cross-sectional study of 86 untreated newly diagnosed HIV-infected patients and 54 matched controls attending a voluntary testing clinic in Cape Town, South Africa. Serum levels of adenosine deaminase (ADA), total immunoglobulin G (IgG), soluble CD14 and lipopolysaccharide-binding protein (LBP) were measured and correlated with CD4 counts, viral loads and expression of CD38 on CD8+ T cells.

Results

ADA, IgG and LBP were all significantly increased in the HIV infected group (p < 0.0001) compared with uninfected controls. Soluble CD14 was also significantly increased (p = 0.0187). Furthermore, all these parameters correlated inversely with CD4 counts (r = −0.481 p < 0.0001; r = −0.561; p < 0.0001; r = −0.387 p = 0.0007 and r = −0.254 p = 0.0240, respectively). Only ADA correlated with viral load (r = 0.260 p = 0.0172). Importantly, ADA, IgG and LBP correlated directly with %CD38 on CD8+ T cells (r = 0.369 p < 0.0001; r = 0.284 p = 0.001; r = 0.408 p = 0.0006, respectively).

Conclusion

Affordable parameters such as serum ADA and IgG correlated significantly with immune activation levels and markers of disease progression in untreated HIV-infection and therefore may add value to the management of these patients in resource-limited settings.
Literature
1.
go back to reference Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231–41.PubMedCrossRef Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol. 2008;214:231–41.PubMedCrossRef
2.
go back to reference Hazenberg MD, Otto SA, van Benthem BHB, Roos MTL, Coutinho RA, Lange JMA, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881–8.PubMedCrossRef Hazenberg MD, Otto SA, van Benthem BHB, Roos MTL, Coutinho RA, Lange JMA, et al. Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS. 2003;17:1881–8.PubMedCrossRef
3.
go back to reference Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RMM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol. 2002;169:3400–6.PubMed Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RMM. CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J Immunol. 2002;169:3400–6.PubMed
5.
go back to reference El-Sadr WM, Lundgren JD, Neaton J, other (the SMART Study Group). CD4+ count- guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.PubMedCrossRef El-Sadr WM, Lundgren JD, Neaton J, other (the SMART Study Group). CD4+ count- guided interruption of antiretroviral treatment. N Engl J Med. 2006;355(22):2283–96.PubMedCrossRef
6.
go back to reference Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. INSIGHT SMART Study Group. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90.PubMedCrossRef Sandler NG, Wand H, Roque A, Law M, Nason MC, Nixon DE, et al. INSIGHT SMART Study Group. Plasma levels of soluble CD14 independently predict mortality in HIV infection. J Infect Dis. 2011;203(6):780–90.PubMedCrossRef
7.
go back to reference Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 survey. J Clin Infect Dis. 2009;48:633–9.CrossRef Bonnet F, Burty C, Lewden C, Costagliola D, May T, Bouteloup V, et al. Changes in cancer mortality among HIV-infected patients: the Mortalite 2005 survey. J Clin Infect Dis. 2009;48:633–9.CrossRef
8.
go back to reference Deeks, Steven G, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. Br Med J. 2009;338:a3172.CrossRef Deeks, Steven G, Phillips AN. HIV infection, antiretroviral treatment, ageing, and non-AIDS related morbidity. Br Med J. 2009;338:a3172.CrossRef
9.
go back to reference Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr. 1993;6:904–12.PubMed Giorgi JV, Liu Z, Hultin LE, Cumberland WG, Hennessey K, Detels R. Elevated levels of CD38+ CD8+ T cells in HIV infection add to the prognostic value of low CD4+ T cell levels: results of 6 years of follow-up. J Acquir Immune Defic Syndr. 1993;6:904–12.PubMed
10.
go back to reference Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr. 1997;16:83–92.CrossRef Liu Z, Cumberland WG, Hultin LE, Prince HE, Detels R, Giorgi JV. Elevated CD38 antigen expression on CD8+ T cells is a stronger marker for the risk of chronic HIV disease progression to AIDS and death in the multicenter AIDS cohort study than CD4+ cell count, soluble immune activation markers, or combinations of HLA-DR and CD38 expression. J Acquir Immune Defic Syndr. 1997;16:83–92.CrossRef
11.
go back to reference Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced immunodeficiency virus type 1 infection is more closely associated with T-lymphocyte activation then with plasma virus burden or virus chemokine receptor usage. J Infect Dis. 1999;179:859–70.PubMedCrossRef Giorgi JV, Hultin LE, McKeating JA, Johnson TD, Owens B, Jacobson LP, et al. Shorter survival in advanced immunodeficiency virus type 1 infection is more closely associated with T-lymphocyte activation then with plasma virus burden or virus chemokine receptor usage. J Infect Dis. 1999;179:859–70.PubMedCrossRef
12.
go back to reference Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534–43.PubMedCrossRef Hunt PW, Martin JN, Sinclair E, Bredt B, Hagos E, Lampiris H, et al. T cell activation is associated with lower CD4+ T cell gains in human immunodeficiency virus-infected patients with sustained viral suppression during antiretroviral therapy. J Infect Dis. 2003;187:1534–43.PubMedCrossRef
13.
go back to reference Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71.PubMedCrossRef Brenchley JM, Price DA, Schacker TW, Asher TE, Silvestri G, Rao S, et al. Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat Med. 2006;12:1365–71.PubMedCrossRef
14.
go back to reference Redd AD, Dabitao D, Bream JH, Charvat B, Laeyendecker O, Kiwanuka N, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci U S A. 2009;106:6718–23.PubMedCrossRef Redd AD, Dabitao D, Bream JH, Charvat B, Laeyendecker O, Kiwanuka N, et al. Microbial translocation, the innate cytokine response, and HIV-1 disease progression in Africa. Proc Natl Acad Sci U S A. 2009;106:6718–23.PubMedCrossRef
15.
go back to reference Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;80:1584–9.CrossRef Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, et al. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. J Infect Dis. 1999;80:1584–9.CrossRef
16.
go back to reference Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010;5(1):PMID:20126452.CrossRef Naeger DM, Martin JN, Sinclair E, Hunt PW, Bangsberg DR, Hecht F, et al. Cytomegalovirus-specific T cells persist at very high levels during long-term antiretroviral treatment of HIV disease. PLoS One. 2010;5(1):PMID:20126452.CrossRef
17.
go back to reference Eltzschig HK, Faigle M, Knapp S, Karhausen J, Ibla J, Rosenberger P, et al. Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. Blood. 2006;108:1602–10.PubMedCrossRef Eltzschig HK, Faigle M, Knapp S, Karhausen J, Ibla J, Rosenberger P, et al. Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26. Blood. 2006;108:1602–10.PubMedCrossRef
18.
go back to reference Cowan MJ, Brady RO, Widder KJ. Elevated erythrocyte adenosine deaminase activity in patients with acquired immunodeficiency syndrome. Proc Natl Acad Sci. 1986;83:1089–91.PubMedCrossRef Cowan MJ, Brady RO, Widder KJ. Elevated erythrocyte adenosine deaminase activity in patients with acquired immunodeficiency syndrome. Proc Natl Acad Sci. 1986;83:1089–91.PubMedCrossRef
19.
go back to reference Gakis C, Calia G, Naitana A, Pirino D, Serru G. Serum adenosine deaminase activity in HIV positive subjects. A hypothesis on the significance of ADA2. Panminerva Med. 1989;31:107–13.PubMed Gakis C, Calia G, Naitana A, Pirino D, Serru G. Serum adenosine deaminase activity in HIV positive subjects. A hypothesis on the significance of ADA2. Panminerva Med. 1989;31:107–13.PubMed
20.
go back to reference Casoli C, Lisa A, Magnani G, Starcich R, Fiaccadori F, Bertazzoni U, et al. Prognostic value of adenosine deaminase compared to other markers for progression to acquired immunodeficiency syndrome among intravenous drug users. J Med Virol. 1995;45:203–10.PubMedCrossRef Casoli C, Lisa A, Magnani G, Starcich R, Fiaccadori F, Bertazzoni U, et al. Prognostic value of adenosine deaminase compared to other markers for progression to acquired immunodeficiency syndrome among intravenous drug users. J Med Virol. 1995;45:203–10.PubMedCrossRef
22.
go back to reference De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, Narita M, et al. Mechanisms of hypergammaglobulinemia and impaired antigen specific humoral immunity in HIV-1 infection. Blood. 2004;103:2180–6.PubMedCrossRef De Milito A, Nilsson A, Titanji K, Thorstensson R, Reizenstein E, Narita M, et al. Mechanisms of hypergammaglobulinemia and impaired antigen specific humoral immunity in HIV-1 infection. Blood. 2004;103:2180–6.PubMedCrossRef
23.
24.
go back to reference FRAM study Modrich L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr. 2010;53(1):102–6.PubMedCrossRef FRAM study Modrich L, Scherzer R, Zolopa A, Rimland D, Lewis CE, Bacchetti P, et al. Association of HIV infection, demographic and cardiovascular risk factors with all-cause mortality in the recent HAART era. J Acquir Immune Defic Syndr. 2010;53(1):102–6.PubMedCrossRef
25.
go back to reference Orsi F, Patrizia M, Carrieri M, Coriat B, Delaporte E, Moatti J-P, et al. Call to action to secure universal access to ART in developing countries. Lancet. 2010;375:1693–4.PubMedCrossRef Orsi F, Patrizia M, Carrieri M, Coriat B, Delaporte E, Moatti J-P, et al. Call to action to secure universal access to ART in developing countries. Lancet. 2010;375:1693–4.PubMedCrossRef
26.
go back to reference Sax PE, Baden LR. When to start antiretroviral therapy—ready when you are? N Engl J Med. 2009;360:1897–9.PubMedCrossRef Sax PE, Baden LR. When to start antiretroviral therapy—ready when you are? N Engl J Med. 2009;360:1897–9.PubMedCrossRef
27.
go back to reference Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS. 2011;25:2123–31.PubMedCrossRef Hunt PW, Cao HL, Muzoora C, Ssewanyana I, Bennett J, Emenyonu N, et al. Impact of CD8+ T-cell activation on CD4+ T-cell recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy. AIDS. 2011;25:2123–31.PubMedCrossRef
28.
go back to reference Perez-Rodriguez E, Jimenez Castro D. The use of adenosine deaminase and adenosine deaminase isoenzymes in the diagnosis of tuberculous pleuritis. Curr Opin Pulm Med. 2000;6:259–66.PubMedCrossRef Perez-Rodriguez E, Jimenez Castro D. The use of adenosine deaminase and adenosine deaminase isoenzymes in the diagnosis of tuberculous pleuritis. Curr Opin Pulm Med. 2000;6:259–66.PubMedCrossRef
29.
go back to reference Zemlin AE, Burgess LJ, Carstens ME. The diagnostic utility of adenosine deaminase isoenzymes in tuberculous pleural effusions. Int J Tuberc Lung Dis. 2009;13:214–20.PubMed Zemlin AE, Burgess LJ, Carstens ME. The diagnostic utility of adenosine deaminase isoenzymes in tuberculous pleural effusions. Int J Tuberc Lung Dis. 2009;13:214–20.PubMed
30.
go back to reference Baba K, Hoosen AA, Langeland N, Dyrhol-Riise AM. Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. PLoS One. 2008;3(7):e2788. 10.1371/journal.pone.0002788.PubMedCrossRef Baba K, Hoosen AA, Langeland N, Dyrhol-Riise AM. Adenosine deaminase activity is a sensitive marker for the diagnosis of tuberculous pleuritis in patients with very low CD4 counts. PLoS One. 2008;3(7):e2788. 10.1371/journal.pone.0002788.PubMedCrossRef
31.
go back to reference Niedzwicki JG, Kouttab NM, Mayer KH, Carpenter CCJ, Parks RE, Abushanab E, et al. Plasma adenosine deaminase2: a marker for human immunodeficiency virus infection. J Acquir Immune Defic. 1991;4:178–82. Niedzwicki JG, Kouttab NM, Mayer KH, Carpenter CCJ, Parks RE, Abushanab E, et al. Plasma adenosine deaminase2: a marker for human immunodeficiency virus infection. J Acquir Immune Defic. 1991;4:178–82.
32.
go back to reference Rani HS, Madhavi G, Srikanth BMV, Jharna P, Rao URK, Jyothy A. Serum ADA and C-reactive protein in rheumatoid arthritis. Int J Hum Genet. 2006;6(3):195–8. Rani HS, Madhavi G, Srikanth BMV, Jharna P, Rao URK, Jyothy A. Serum ADA and C-reactive protein in rheumatoid arthritis. Int J Hum Genet. 2006;6(3):195–8.
33.
go back to reference Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol. 2010;84(22):12082–6.PubMedCrossRef Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, et al. Reduction of immune activation with chloroquine therapy during chronic HIV infection. J Virol. 2010;84(22):12082–6.PubMedCrossRef
34.
go back to reference Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev. 2001;14:753–77.PubMedCrossRef Lawn SD, Butera ST, Folks TM. Contribution of immune activation to the pathogenesis and transmission of human immunodeficiency virus type 1 infection. Clin Microbiol Rev. 2001;14:753–77.PubMedCrossRef
35.
go back to reference Amadori A, Gallo P, Zamarchi R, Veronese ML, DeRossi A, Wolf D, et al. IgG oligoclonal bands in sera of HIV-1 infected patients are mainly directed against HIV-1 determinants. AIDS Res Hum Retroviruses. 1990;6:581–6.PubMedCrossRef Amadori A, Gallo P, Zamarchi R, Veronese ML, DeRossi A, Wolf D, et al. IgG oligoclonal bands in sera of HIV-1 infected patients are mainly directed against HIV-1 determinants. AIDS Res Hum Retroviruses. 1990;6:581–6.PubMedCrossRef
36.
go back to reference Konstantinopoulos PA, Dezube BJ, Pantanowitz L, Horowitz GL, Beckwith BA. Protein electrophoresis and immunoglobulin analysis in HIV-infected patients. Am J Clin Pathol. 2007;128:596–603.PubMedCrossRef Konstantinopoulos PA, Dezube BJ, Pantanowitz L, Horowitz GL, Beckwith BA. Protein electrophoresis and immunoglobulin analysis in HIV-infected patients. Am J Clin Pathol. 2007;128:596–603.PubMedCrossRef
37.
go back to reference Van Vuuren M, Zemlin AE, Germishuys JJ. Monoclonal gammopathy and other serum protein electrophoresis patterns in patients with HIV infection in South Africa. Ann Clin Biochem. 2010;47:366–74.PubMedCrossRef Van Vuuren M, Zemlin AE, Germishuys JJ. Monoclonal gammopathy and other serum protein electrophoresis patterns in patients with HIV infection in South Africa. Ann Clin Biochem. 2010;47:366–74.PubMedCrossRef
38.
go back to reference Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, Seebregts C, et al. Persistent microbial translocation and immune activation in HIV-1–infected South Africans receiving combination antiretroviral therapy. J Infect Dis. 2010;5:723–33.CrossRef Cassol E, Malfeld S, Mahasha P, van der Merwe S, Cassol S, Seebregts C, et al. Persistent microbial translocation and immune activation in HIV-1–infected South Africans receiving combination antiretroviral therapy. J Infect Dis. 2010;5:723–33.CrossRef
39.
go back to reference Piconi S, Parisotto S, Rizzardini G, Passerini S, Argenteri RT, Meraviglia BP, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, ART-treated, immunological non responders. Blood. 2011;118:3263–72.PubMedCrossRef Piconi S, Parisotto S, Rizzardini G, Passerini S, Argenteri RT, Meraviglia BP, et al. Hydroxychloroquine drastically reduces immune activation in HIV-infected, ART-treated, immunological non responders. Blood. 2011;118:3263–72.PubMedCrossRef
Metadata
Title
Serum Adenosine Deaminase and Total Immunoglobulin G Correlate with Markers of Immune Activation and Inversely with CD4 Counts in Asymptomatic, Treatment-Naive HIV Infection
Authors
Hayley Ipp
Annalise E. Zemlin
Richard H. Glashoff
Johan van Wyk
Naadira Vanker
Tim Reid
Linda-Gail Bekker
Publication date
01-04-2013
Publisher
Springer US
Published in
Journal of Clinical Immunology / Issue 3/2013
Print ISSN: 0271-9142
Electronic ISSN: 1573-2592
DOI
https://doi.org/10.1007/s10875-012-9832-7

Other articles of this Issue 3/2013

Journal of Clinical Immunology 3/2013 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine